<SEC-DOCUMENT>0001193125-16-578634.txt : 20160505
<SEC-HEADER>0001193125-16-578634.hdr.sgml : 20160505
<ACCEPTANCE-DATETIME>20160505070033
ACCESSION NUMBER:		0001193125-16-578634
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160505
DATE AS OF CHANGE:		20160505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		161621500

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d189793d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;5, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Dublin 2, Ireland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2016, Amarin Corporation plc issued a
press release announcing its financial results for the three months ended March&nbsp;31, 2016 (the &#147;Press Release&#148;). A copy of the Press Release is furnished herewith as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information in this report furnished pursuant to Item&nbsp;2.02 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if
such subsequent filing specifically references the information furnished pursuant to Item&nbsp;2.02 of this report. </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May&nbsp;5, 2016</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;5, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John F. Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated May 5, 2016</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d189793dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189793img.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Product revenue up 63% over prior year </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>REDUCE-IT cardiovascular outcomes study achieves target enrollment </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Preparation for interim analysis by independent data monitoring committee underway </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Management to host conference call at 8:00 a.m. ET today </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, May 5, 2016 &#151; Amarin Corporation plc&nbsp;(NASDAQ: AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular health,&nbsp;today announced financial results for the quarter ended March 31, 2016, and provided an update on company operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key Amarin achievements since December 31, 2015 include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Revenue growth</U>: Recognized $25.3 million in net product revenue from Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sales in Q1 2016 compared to $15.6 million in Q1 2015, an increase of
approximately 63%; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Gross margin</U>: Gross margin on product sales increased to 73% in Q1 2016 compared to 64% in Q1 2015 primarily reflecting lower cost of inventory purchases due to expanded supplier network and higher purchasing
volumes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Prescription growth</U>: Increased normalized prescriptions, based on data from Symphony Health Solutions and IMS Health, by 55% and 56%, respectively, compared to Q1 2015, reflecting its ninth consecutive quarter of
greater than 50% growth in normalized prescriptions over the corresponding quarter in the prior year; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>Expanded marketing</U>: Agreement reached with FDA and U.S. government allowing Amarin to engage in promotion of ANCHOR Phase 3 clinical trial results and other related truthful and non-misleading information
relating to Vascepa; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>REDUCE-IT R&amp;D progress</U>: REDUCE-IT cardiovascular outcomes study, designed to provide data to support a significantly expanded market opportunity for Vascepa, reached target enrollment of approximately 8,000
patients and the onset of approximately 60% of the target aggregate number of primary cardiovascular events within the study has triggered preparation for a protocol pre-specified interim efficacy analysis by the independent Data Monitoring
Committee (DMC) expected to be conducted in September or October 2016; and </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><U>International commercialization</U>: With Amarin&#146;s support, Eddingpharm, the company&#146;s partner, completed submissions to China Food and Drug Administration needed to better define the clinical and
regulatory pathway to Vascepa approval in China. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amarin&#146;s passionate field organization and managed care teams leveraged the
strong underlying data that differentiates Vascepa&#146;s clinical profile from its omega-3 competitors to increase managed care coverage and drive greater utilization, resulting in our strongest first quarter yet,&#148; commented John F. Thero,
president and chief executive officer of Amarin. &#147;Our net product revenue exceeded our internal revenue expectations for the quarter and our market share continued to expand approaching 20% of the current prescription <FONT
STYLE="white-space:nowrap">omega-3</FONT> category. On the clinical development front, REDUCE-IT remains on schedule and our confidence remains high that this important study is positioned for success. As we look toward the balance of 2016, our
focus remains on executing on REDUCE-IT, driving U.S. revenue growth and continuing to opportunistically increase shareholder value.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial
Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&#146;s continued year-over-year revenue growth resulted primarily from increased volume of Vascepa prescribed, with the number of
physicians prescribing Vascepa and rate at which they do so both increasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Normalized prescriptions (estimated) for the first quarter of 2016, based on
data from Symphony Health Solutions and IMS Health, totaled approximately 201,000 and 214,000, respectively. These prescription levels represent growth of approximately 55% and 56%, respectively, compared to the same quarter in 2015. As has been
true in the first quarter of prior years for Vascepa and many other drugs, product revenue and prescription growth were impacted by the reset of patient deductible amounts for many healthcare plans at the beginning of the calendar year which
negatively affect prescription refills by patients at retail pharmacies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REDUCE-IT Cardiovascular Outcomes Study Achieves Target Enrollment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the first quarter of 2016, Amarin&#146;s REDUCE-IT cardiovascular outcomes study reached its target enrollment and now has over 8,000 patients enrolled
in this study evaluating the effectiveness of Vascepa in preventing the occurrence of a first major cardiovascular event in a population of patients at high residual risk despite statin therapy.&nbsp;This is the first prospective double-blinded
cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels. Unlike outcomes studies for many drugs that are designed to validate a currently approved drug indication, a
positive result in REDUCE-IT could potentially expand the market opportunity for Vascepa, reflecting a potential market opportunity comparable in size to cholesterol management therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cardiovascular event rate in this events-driven study continues to track to prior estimates. Late in the first quarter, the onset of approximately 60% of
the target aggregate number of primary cardiovascular events triggered formal preparation for a protocol pre-specified interim efficacy and safety analysis by the independent Data Monitoring Committee (DMC).&nbsp;The interim analysis is anticipated
to occur in September or October 2016, after all patients in the study complete a study visit and the data are collected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and prepared for transfer to and analysis by the DMC. The study has undergone multiple prior safety analyses by the DMC with each analysis resulting in a DMC recommendation that REDUCE-IT
continue as planned.&nbsp;The pending interim analysis in September or October 2016 will represent the first review of unblinded efficacy data by the DMC. Amarin will remain blinded to the interim and ongoing results of the REDUCE-IT study until
after the study is ready to be stopped either at the interim analysis or at the final analysis. Given the nature of outcomes studies and the design of REDUCE-IT, Amarin expects the DMC will recommend that REDUCE-IT continue until attainment of 100%
of the target 1,612 primary events, which is estimated to occur in 2017 with results anticipated to be published in 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net product revenue for the three months ended March 31, 2016 and 2015 was $25.3 million and $15.6 million, respectively.&nbsp;This increase in product revenue
was primarily attributable to increases both in new and recurring prescriptions of Vascepa. In addition, licensing revenue during the three months ended March 31, 2016 and 2015 was $0.2 million and $0.4 million, respectively. Based on first quarter
2016 results and anticipated trends, the company reiterates its guidance estimate of total 2016 net product revenue of between $105 million and $120 million. Revenue within this range is expected to position Amarin to enter 2017 cash flow positive
from commercial operations, excluding REDUCE-IT and other R&amp;D expense not required to sustain current commercial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of goods sold
during the three months ended March 31, 2016 and 2015 was $6.9 million and $5.6 million, respectively.&nbsp;Gross margin on product sales improved to 73% in the quarter ended March 31, 2016 compared to 64% in the quarter ended March 31,
2015.&nbsp;The improvement in gross margin on product sales was primarily driven by lower unit cost active pharmaceutical ingredient purchases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling,
general and administrative, or SG&amp;A, expense in the three months ended March 31, 2016 and 2015 was $28.0 million and $24.7 million, respectively.&nbsp;This increase in expense primarily reflects increased co-promotion fees earned by Kowa
Pharmaceuticals America, Inc., increased sales and marketing spend associated with Amarin&#146;s expanded marketing initiatives, and an increase in non-cash stock-based compensation expense, partially offset by quarterly variability in legal costs.
Co-promotion fees for the three months ended March 31, 2016 and 2015 were $3.5 million and $1.5 million, respectively. Amarin currently anticipates that prior to REDUCE-IT data, with the exception of increases in co-promotion fees expected to be
earned by Kowa Pharmaceuticals America, Inc. and non-cash costs, its SG&amp;A expense taken as a whole will be relatively flat during 2016 as compared to 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense in the three months ended March 31, 2016 and 2015 was $13.7 million and $12.6 million, respectively. This increase in expense
was primarily driven by the timing of REDUCE-IT expenses.&nbsp;Research and development costs in 2016, excluding non-cash costs, are expected to be similar in aggregate to 2015 including annual REDUCE-IT costs of approximately $30 million to $40
million until study completion with quarterly variability due to the timing of study-related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under GAAP, Amarin reported a net loss of $29.8
million in the first quarter of 2016, or basic and diluted loss per share of $0.16.&nbsp;This net loss included $3.6 million in non-cash share-based compensation expense and a $1.3 million non-cash loss on the change in fair value of derivatives.
Amarin reported a net loss of $32.0 million in the first quarter of 2015, or basic and diluted loss per share of $0.18.&nbsp;This net loss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
included $3.0 million in non-cash share-based compensation expense, a $0.5 million non-cash gain on the change in fair value of derivatives, and a $0.9 million non-cash deemed dividend for
accounting purposes related to a preferred stock purchase option.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Excluding non-cash gains or losses for share-based compensation, warrant compensation,
change in fair value of derivatives, and the non-cash deemed dividend, non-GAAP adjusted net loss was $24.9 million for the first quarter of 2016, or non-GAAP adjusted basic and diluted loss per share of $0.14, compared to non-GAAP adjusted net loss
of $28.6 million for the first quarter of 2015, or <FONT STYLE="white-space:nowrap">non-GAAP</FONT> adjusted basic and diluted loss per share of $0.16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin reported cash and cash equivalents of $81.4 million as of March 31, 2016. Net cash used in operating activities in the quarter ended March 31, 2016
increased year-over-year primarily as a result of $15.0 million in up-front proceeds from the Eddingpharm license agreement received in the corresponding quarter of 2015. Increased sales and marketing spend in 2016 in support of expanded Vascepa
promotion was more than offset by higher collections from product sales. As of March 31, 2016, Amarin reported $15.0 million in net accounts receivable ($19.3 million in gross accounts receivable before allowances and reserves) and $21.3 million in
inventory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2016, Amarin had approximately 184.4 million American Depository Shares (ADSs) and ordinary shares outstanding, 32.8 million
common share equivalents of Series A Convertible Preferred Shares outstanding and approximately 20.8 million equivalent shares underlying stock options at a weighted-average exercise price of $3.41, as well as 10.7 million equivalent shares
underlying restricted or deferred stock units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&nbsp;will host<B> </B>a conference call at&nbsp;8:00 a.m. ET&nbsp;today,&nbsp;May 5, 2016.&nbsp;The conference call can be heard live on the investor
relations section of the company&#146;s website at www.amarincorp.com, or via telephone by dialing 877-407-8033 within the United States or <FONT STYLE="white-space:nowrap">201-689-8033</FONT> from outside the United States. A replay of the call
will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (inside the United States) or 201-612-7415 (outside the United States). A replay of the call will also be available
through the company&#146;s website shortly after the call. For both dial-in numbers, please use conference ID 13635415. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Non-GAAP Adjusted
Financial Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Included in this press release and the conference call referenced above are non-GAAP adjusted financial information as defined
by U.S. Securities and Exchange Commission Regulation G.&nbsp;The GAAP financial measure most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted
financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-GAAP adjusted net loss was derived by taking GAAP net loss and adjusting it for non-cash gains or losses for
share-based compensation, warrant compensation, change in value of derivatives, gain on extinguishment of debt and preferred stock purchase option and beneficial conversion features. Management believes that these non-GAAP adjusted measures provide
investors with a better understanding of the company&#146;s historical results from its core business operations. While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors
regarding the underlying performance of the company&#146;s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.
Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the company&#146;s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures
may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a
biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.&nbsp;Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential
therapeutic benefits of polyunsaturated fatty acids.&nbsp;Amarin&#146;s clinical program includes a commitment to an ongoing outcomes study.&nbsp;Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl), Amarin&#146;s
first FDA-approved product, is a highly pure omega-3 fatty acid product available by prescription.&nbsp;For more information about Vascepa, visit www.vascepa.com.&nbsp;For more information about Amarin, visit www.amarincorp.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules are a single-molecule prescription product consisting of 1
gram of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and
protect the single molecule active ingredient. Vascepa is known in scientific literature as AMR101. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FDA-approved Indication and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of VASCEPA on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for VASCEPA </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">VASCEPA&nbsp;is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to&nbsp;VASCEPA&nbsp;or any of its components. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt;3% and greater than placebo.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients receiving treatment with&nbsp;VASCEPA&nbsp;and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients should be advised to swallow&nbsp;VASCEPA&nbsp;capsules whole; not to break open, crush, dissolve, or chew&nbsp;VASCEPA. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-855-VASCEPA&nbsp;or&nbsp;the&nbsp;FDA&nbsp;at&nbsp;1-800-FDA-1088.</FONT></FONT></FONT></FONT></FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL
VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT&nbsp;<U>WWW.VASCEPA.COM</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the United States Food and Drug
Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 500 mg/dL) hypertriglyceridemia. Vascepa is under various stages of development for potential use
in other indications that have not been approved by the FDA. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements, including statements about the future commercialization of Vascepa; expectations regarding Vascepa sales, revenue, expense and other financial metrics for the quarter ended March 31, 2016; expectations related to
Amarin&#146;s anticipated financial position and outlook in 2016 and the years that follow such as the company&#146;s potential to enter 2017 as cash flow positive from commercial operations excluding certain expenses; expectations for event rates,
interim data review, results and related announcements with respect to Amarin&#146;s REDUCE-IT cardiovascular outcomes study; expectations related to the interim and final outcome of the REDUCE-IT study and the anticipated successful completion of
the REDUCE-IT study, including the potential impact on the market opportunity for Vascepa in the event of a positive result in the REDUCE-IT study; and statements regarding the potential efficacy, safety and therapeutic benefits of
Vascepa.&nbsp;These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.&nbsp;In particular, as disclosed in filings with the U.S. Securities and Exchange Commission, Amarin&#146;s ability to
effectively commercialize Vascepa will depend in part on its ability to continue to effectively finance its business (including the REDUCE-IT study), efforts of third parties, its ability to create market demand for Vascepa through education,
marketing and sales activities, to achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with
legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa.&nbsp;Among the factors that could cause actual results to differ materially from those described or projected
herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that historical REDUCE-IT clinical trial event rates may not be predictive of future results
and related cost may increase beyond expectations; the risk that regulatory reviews may impact the current design of the REDUCE-IT study or cause a change in strategic direction with respect to continuation of the study; the risk that future
litigation, court decisions and interpretation and interactions with regulatory authorities may impact Vascepa marketing and sales rights and efforts; the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
risk that Vascepa may not show clinically meaningful effects in REDUCE-IT or support regulatory approvals for cardiovascular risk reduction; and the risk that patents may not be upheld in patent
litigation and applications may not result in issued patents.&nbsp;A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities
and Exchange Commission, including its most recent Quarterly Report on Form 10-Q.&nbsp;Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date
hereof.&nbsp;Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information Regarding Prescription Data and Product Revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical prescription data provided in this press release are based on data published by third parties. References to normalized prescriptions equate to
120 capsules or one month&#146;s supply. Although Amarin believes these data are prepared on a period-to-period basis in a manner that is generally consistent and that such results are indicative of current prescription trends, these data are based
on estimates and should not be relied upon as definitive. These data may overstate or understate actual prescriptions. Based on other data available to Amarin and the history of such third-party prescription estimates in similar stages of launch of
other pharmaceutical products, Amarin believes that the trends provided by this information can be useful to gauge current prescription levels. There is a limited amount of information available to determine the actual number of total prescriptions
for prescription products like Vascepa. Amarin believes that investors should view these data with caution, as data for this single and limited period may not be representative of a trend consistent with the results presented or otherwise predictive
of future results. Seasonal fluctuations in pharmaceutical sales may affect future prescription trends of Vascepa on a monthly and quarterly basis, for example, as could changes in prescriber sentiment and other factors. Amarin believes investors
should consider its results during this quarter together with its results over several future quarters, or longer, and in light of seasonal fluctuations, before making an assessment about potential future performance. The commercialization and
co-promotion of a new pharmaceutical product are complex undertakings, and Amarin&#146;s ability to effectively and profitably commercialize Vascepa will depend in part on its ability to continue to generate market demand for Vascepa through
education, marketing and sales activities, its ability to achieve market acceptance of Vascepa, its ability to generate product revenue and its ability to receive adequate levels of reimbursement from third-party payers and its ability to benefit
from continued contributions of its Vascepa co-promotion partner, Kowa Pharmaceuticals America, Inc. See &#147;Risk Factors&#151;Risks Related to the Commercialization and Development of Vascepa&#148; included in Part II, Item 1A. <I>Risk
Factors</I> in Amarin&#146;s most recent Quarterly Report on Form 10-Q. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information about Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations
website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs,&nbsp;Securities and Exchange Commission&nbsp;filings, press releases, public conference calls and webcasts.&nbsp;The
information that we post on these channels and websites could be deemed to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material information.&nbsp;As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor
relations website, on a regular basis.&nbsp;This list of channels may be updated from time to time on our investor relations website and may include social media channels.&nbsp;The contents of our website or these channels, or any other website that
may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations:
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathryn McNeil</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908)
719-1315 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M.
Stern </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (646) 378-2992 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristie Kuhl </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finn Partners </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (212) 583-2791 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kristie.kuhl@finnpartners.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEET DATA </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(U.S. GAAP) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-Term Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">816,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,149,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,119,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(156,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(129,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS DATA </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(U.S. GAAP) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) gain on change in fair value of derivative liabilities (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss applicable to common shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Excluding non-cash stock- and warrant-based compensation, selling, general and administrative expenses were $25,136 and $22,519 for the three months ended March 31, 2016 and 2015, respectively, and research and
development expenses were $13,017 and $11,803, respectively, for the same periods. Excluding these non-cash costs and excluding co-promotion fees paid to our U.S. co-promotion partner, selling, general and administrative expenses were $21,638 and
$21,029 for the three months ended March 31, 2016 and 2015, respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Non-cash gains and losses result from changes in the fair value of a warrant derivative liability, long-term debt derivative liabilities, and a preferred stock purchase option derivative liability. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECONCILIATION OF NON-GAAP NET LOSS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for EPS<SUP STYLE="font-size:85%; vertical-align:top">1 </SUP>- GAAP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant compensation income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on change in fair value of derivatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss for EPS<SUP STYLE="font-size:85%; vertical-align:top">1 </SUP>- non
GAAP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;basic
and diluted</P></TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted - non GAAP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g189793img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189793img.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 00$Q P$1  (1 0,1 ?_$ -0   (#  (# 0$
M       *" D+! <!!08" P$  @,! 0$!              8$!0<# 0(($
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MA8UKJ4>X-)PK45!PQ42XU".T>(WL>XD5P /9M(45E.]+QH2$Y0P)S[5 F_\
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M175O1^C6W])?]O0\/Z23-0I\W)^(J1/TO&__ ,F4D/7IQLRJ [;B ?\ +5&
M.O\ !WVU"ZX)_1>PS-]:[:6/[XW@?05HC)@)E"==_P",3'[ Z&W'I^C6--<2
MVFVJ;/M5V46=!A/MNM.Y9S9[NV.(BS&I^6<9Y#RCD##DP\6$*NZM:N>K;%.Z
MU<6Y45530=D8F!#YI+95BMX%@ Y0.F;:;[6SHVGV,Q:'6\C6M?OIR@U'#;YD
MF6UHZYE?%%7G;S$#8:'([L\/.J*,J8JR%A+(EPQ'ENHRU'R'19EW7K;4YUL9
M!_&R+4VP@/B#RW;%VB(+-G"8F1<H'*HF8Q3 .F>VGANH6SQ$.@>*A17!S20:
MAPV;NSN3:782[WAZXM3N#',6X>*O+'95OCQFBS/1$T*N<Y6\7BB_2[LXB,0L
M82HPDDL;=N/A:+&\ I&+GW5G2XD!U'36TE'QM'V@-H[?3Z;?3M0$!$,Y/@G(
M_=/^[Z."=A+T  VVW\6P!Z-@'U?=K,@11,IWJ@WZEJ)C'W:?RL_>,&KE[ Y+
MPU*0CQ=%-1Q%2*UX8QBSU@J8!.V<*QT@L@<Q1 3)*F*/0=-O1#W?K;0QU&.8
MX<0 "/.JG66CY9I(]\/%#Y599VYH.)KW [A?%PD:UB8Y#C+A-PFQ8H$;-DW$
MA0H:1?J@D3P@"KR0=K+*&V$3JJ&,/4=4.K.?)JUP^:I?XKAY#0=U%-LJ,LXV
MM  +<?*IP:@J2J5NYMEPF/\ *N.XL.[E6NWB=UCYQ(*8UF<:X]O+J]D4L4DW
M1O1'EP;+OF#9 6IV'EI"")C-Q-^MOIFT2$26[G&Q^:'/\7-2F ]WU]ZJ-0>Y
MLH#;CPO=RH37$XX>3N59+GD\X\11:?4]8Q*GX1\?S7'S"AC>+?IX12;I@ ;?
M;UWU>"U;LT9Q/XE6F26O\:/(Y>A><KI)$_@1^I]Q4"A#?C _&O%CDABB7Q?Q
M(-&NRJGV !C=>GIU]"R82#^C'$T^/ZQ1>>-(#0WF/X7>Q4P\=,XM.4W.F^<H
M.5G=A88(N."3?LCQZSS;<40,I9[Q$MWEAAXR2K>-RQ#BF4R-"NN5GJQU"&<$
M=R)=O$KXE"LEW"+'3&V5E9"6-_Q1AX:!45/,XXG'#ZE$83+-SS2%L@H[FHXX
MC++'+%7JP_+*K' %$_J::\Z;>5^,SWCIA9!0J:70QBG>0".RV_I$P"80]6E2
M2S?2HT@?_)["K 3!QPO'5_"[UA,"8NQ@3(O%-GC3-N7B<M(#*E!FXVPY2DJI
M7:@AE#'V2&CQ=@LG7:NF2"9MPJTPDFV60*4ZGED7'901TFW%X8-2,]O%X#XW
MBC 2149XGMKW*]CA\6T\*9_.T@XY5'M&'>LO3GGQ#MW!CE=ESC7;"NG"-*G5
M'5'L#E(R9;?C2<$\A1K0@8?PJF>PYBHN?".Q'K==/TEUN^E:A%JEA'=QTJYM
M'=A&8[BD^:)\$AB?\0/^CS8J2?9SYVNN _-F@Y FY%PVP]D8[?%>;V93F%M^
MQ=B?()Q]I.AOX#.J-/BA(E-MXOER+I@( H.H/4FDMU;2GPD#QF^\P]HR'?DN
MEG<NM9VRC%H./#;[>Y:C+-TV>M6SQDX1=LGC=!VS=MCD5;/&CE(JS9VW63$Q
M%D'*)RG(8!$!*(#K"J/:2QXH]IH>(P/!.O,U_O--0<:]AR7)#[_1KU>)5/+9
M"$^JQXZ&*4I3*<87!CB =3F+BK+!"F,(==P*4 W^P-/L3Z="2T_K#^V$ONQU
ML=W[*IB^I+X1FXW\TT^0=1B!9XLY:-GUN5.V;^6PALR09&S;(<28Q2@DBI8D
M%&TTD7H)U'#D0W\ [,?1.JF]TP6LAK-#AQ&P]PP[E$U.W\&Y<1\#\1Z_/ZEU
M!]/YSD_J>\ZJU3[;,A'X;Y-A&XCO'S2_EQT/:W+P38SMRPG,5%O\A8G L5U1
M]#60/N.Q=2^K=+_4=*)8*SPGF;3;08CO&/%<M/N/EKD/)HTX.X';W&E5H6<I
M>0U*XH\?,O\ (;(+E)O6L34F:M+ANJH5-26DV: I05>:]?XQ]8)M5!FD4NXB
M=7?U:QVPLW:G>1V<0)<YWD'VCW )JN9OEH'3'.F''8%1?V2>/=W-Q?Y2=P[/
M#<[G/_/T,BY&6>OTS _A<4H,IY6JQK7SOXYNPG'ZBKM-/H7Y)%GL&Q0TW=27
MC#J-OH]I3Y6W+!AES&E/(/.52Z=;UM9KN3%[FN /<>8]YP[EGO.!#YQY_.W?
MZ/\ C"G7].M;;B [93T!4.0'!:&WTM_]F3*_ZT&8?\BT#6.=<?YXW^P;Z2F;
M1/X5_P"/U!,;;^KTCMOL'I'KL !]XCI/J KFE4J/S)\_NW=XS$W!F$44F.)_
M XY<K<EG#14QX:Q9 3.S4>55XNE_%'<@M\G )D$1\ JR)@_4$=/^G4Z?Z=DU
M)XI?W.# =@(]T^EWD2[<G]0U$6[3^4P$=U?>/EP4#OJ>N *>.<ETOG5C2N),
MJ7E,8['6:6D2T!%A!9%AF -J;9U4D"%1:-;=6V0,5#;;"[8$W_$KJUZ(UEUS
M;NT^X-9F&K:YEISKVCT$+AJEJR"9KXQRQOKW$>W/RI?[@'S%N/ [E;BODA41
M=.V55E@C,@5MNJ)27+&<Z=)I<ZRL3<"**K1Q?F&@FZ)OFR)_X.FW6-.AU6PD
MM'"O,,#N*KX)7PRMD8:.:1]/(M7?'&0J?EN@TW)^/IIM8Z-?ZO"W"I3K(Y5&
MLI S[!"1CG9#%$P 8S=P '(.QB* 8H@ @.L!FMY;6Y?:S"CXS0\1[=B=8I63
M0MFCQ:[Z>9?:>$3= ](ZYO\ A/!=6_$%GA?5%-C(]R^)6,8HE><;,8*IE !W
M(5*=NS<0,(]!$3I"(;>K6Q="?Y,?[4^I*6K?QA'\D>A05[+69,4<?^Y1QZR[
MFZ_5_&.-*@3(RM@NEH<':0<8>4QQ9X:+1=N4TEC)"_DGZ:*8^$0$Y@ =O3JV
MZFMIKS1Y;>V:73&E -M""5&LY&PW#9'FC*BNWT)ZK)W??[5N,ZC(6A+EA3LC
M.FR"HL*IBN/G;G:IER0@F3:,6;>+08-SJ& "@HZ<-T2B;<QP#?64V_26N3R!
MA@+"X_$XB@QQR*8Y=6LF8AQ=CD ?70)$/N!\L<R=VGF1/Y:I.(KO(MDH6'H&
M*,7U&#E;M9*]08-P]6C?SDM=9/ 5FYN5E'+UXH0I6Y%E_*(82)E$=6TC3[?0
M-/%O(X$M-7.) !<?IAV );GG?=3&9PQ.P5P \_'M*8G[ G9:SG@G,$?S:Y:5
MIQC*=K%?FXW"V()0[=2X)2-JC5H:4O-X;-E7"->(R@7:[=A'',+LRCDRRQ4O
M+(4R9U?U/:7%L[2[%P?S.'.X; #\(.W+9EWJVTNPD\47$K2UC<14&I/#9WIQ
M'U:SO8F%N+JK,R^H5_M;.37\PQ%_HKJVMOZ2_P"WX.']))FH?Q<GXBI,_2W!
M_P#9-9A'_P!-&2=ON_SEHP:@]<G_  0;O&;Z"NVE#^_-_"[T+0X1Z*D#[#A_
M=UC;,B-M4V)/7L,CMW<>[Z(>NSY"#_?<D[07]SIK2NKO\@L/YO[ 2WHYI>OI
MA\?[85GG>4[/5,[B^.CY!QTA"TWEMCJ$73HUM6*1G'9)A6I3N2XUOK@A/&LB
ML<!")D3B92-<*"41%NH<H4/3?43](F^5F)-@_.N);V\-_E4_4=/;<#Q8!24
M5'WL/3Z=JS@;Y0[IC"YV?'&1:S,4J^4J9>5VUU6>:*,)F!FXY84G3%VW/L8J
MB9R@9-0HB10@E43,8IBF'9H98[F)LL3@8WMP(QPW#BE>AJ:X)T7L*=[W]MTZ
M?P<YB6XH7-JV:USC_F6QO2D"X-&Y"-XS%]YDW1RA^U39),J</(*GWD" #=4?
M/!,5,TZKZ8Y*ZMI[2&._>, P_$/6.\*[T[4.0"VG-(\FGU$]NS=DK%_J65U$
MNTOF$A0#^49'PN@IX@ZE)^WL:L(AU_";Q(A^YJFZ(QUQ@.!$;J^U3=9HVU%?
MOBGG5I7!$-N%7#[[^,^#!^X _HVKVWLU1:I4ZG/7^N?Z2I=EA9Q _<"EWJ$I
M*J]YU-N5JN0*B? 2/;Q5KG[%'),EYAHV!2[K383DANG6%(D/ER5(D<=,1\?B
M.+LRO0 VW8-(?9-A<+IUVU_/AX7PTH,^W/NHJJ_$ID'((2.7[?+7/MV*OY]$
M]R0Q11)2>Q+()"7Q>%<+2F4YPW$I1349*AZ #8?5OJW\32*_O-3\Z@ALXQI9
MD_S?8J=.[=R$Y@8CPS$8(RGB[M7M)+DXI(4R'D^)\&:?RG7HIBZA_P V=IR,
M]'M6%38S:K]*/*^\0+;J*>6)!(8Y6+0+>SN9S<VTE\?"I[LCCRFH.PTKPQS"
M@W<K@?!D;!0BI+ TTH<*D&HWC#&A"F?PTX[\Y^+.!:+A&ER?9)DXR#:.I1>6
MR79)>YY$F)RPNE)B55M<RS6^6?2S15S\L(MOY,1)N4B?X"@(P-1N[&]NG3R?
MJ37'"C X-PW"BZV\4L;*#Y9P)J"\L)%<L=RGKC6"[B4W8H"'>L.R;/,5YU@,
MS$46(M[ZQ.J^#I \R$&R;BLF>6&,(L*(J$,GY@ )_P (#JHN)=,AB<XR:DW
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MT^<GG385%6+Q5,?&F8/"<=NNPZYW.O:Q>1&&YG+HSF.5HPW8#:AFG64;P]C
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MUQ:VL+;>"T+8FMH*.& \BY.T:9Q+C("X\5[/!OTQW)KC3DB&R]@;N3I8OR1
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*0C0A&A"-"%__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
